Published 2 days ago • loading... • Updated 2 days ago

XORTX Announces USD $3 Million Offering

XORTX Therapeutics Inc. Announced a non-brokered private placement on May 19, 2025, in Calgary to raise up to USD $3,000,000.
The company, a late stage clinical pharmaceutical developer of therapies for progressive kidney disease and gout, initiated the Offering to fund development efforts.
The Offering involves issuing as many as 3,409,090 common share units at a price of USD $0.88 each, with each unit including a Warrant that can be exercised to buy one additional common share at USD $1.20 anytime within 60 months.
If the Nasdaq closing price of XORTX’s common shares remains above USD $2.00 for at least ten consecutive trading sessions, the Warrants will be subject to acceleration and will expire 30 business days after the Company issues a notice.
The funds raised may support XORTX’s ongoing clinical trials but forward-looking statements acknowledge risks including financing, trial success, and intellectual property uncertainties.

Insights by Ground AI

Does this summary seem wrong?

12 Articles

All

Left

Center

Right

NiagaraFallsReview.ca

+11 Reposted by 11 other sources

Lean Left

XORTX Announces USD $3 Million Offering

CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and…

2 days ago·Niagara Falls, Canada

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year